Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 11/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745325 | 0.89 | MEN1 (0.47) | USP5CNR1GAA | |
| SCHEMBL5746178 | 0.87 | USP5 (0.58) | USP5PTGDR2GAATP53HDAC6 | |
| SCHEMBL5748224 | 0.84 | HTT (0.52) | GAA | |
| SCHEMBL5750977 | 0.84 | PTGDR (0.50) | USP5PTGDR2GAAHDAC6 | |
| SCHEMBL4212900 | 0.82 | ALDH1A1 (0.57) | CNR1PTGDR2GAA | |
| SCHEMBL13805196 | 0.81 | CNR1 (0.67) | CNR1GAA | |
| SCHEMBL13805063 | 0.80 | CNR1 (0.48) | CNR1PTGDR2GAA | |
| SCHEMBL6346332 | 0.80 | ALDH1A1 (0.52) | GAA | |
| SCHEMBL5746850 | 0.80 | PTGDR2 (0.42) | USP5PTGDR2GAA | |
| SCHEMBL5749155 | 0.79 | TSHR (0.47) | USP5PTGDR2GAAHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | USP5 2874/4885CNR1 218/4885PTGDR2 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.